Shanghai INT Medical Instruments Co., Ltd. (INT Medical) has signed two share-transfer agreements to purchase a combined 3.49 million shares, equal to 23.18% of Valgen Holding Corporation, for US$107.76 million (approximately RMB 737.79 million). The transactions were executed on 11–12 May 2026 with multiple independent sellers.

The consideration mirrors the sellers’ original investment costs and will be settled in cash. At least 70% of the purchase price is payable at closing; the remaining balance will be released after the sellers complete tax-reporting obligations under PRC Announcement No. 7.

Closing is subject to customary conditions, including regulatory approvals, completion of due diligence, and a six-month long-stop period. Settlement will take place remotely within 15 business days once all conditions are met.

Valgen Holding is a Cayman-incorporated parent that owns 100% of Hangzhou Valgen Medtech Co., Ltd., developer of interventional devices for mitral and tricuspid valve disease. Four products have secured approval under the NMPA’s Innovative Medical Device Special Review Procedure, with DragonFly™ Transcatheter Mitral Valve Clip System being the first domestically approved product of its kind in China.

Financially, Valgen reported: • 2025 revenue of RMB 205.88 million and net profit of RMB 49.57 million, reversing a RMB 40.35 million loss in 2024. • Total assets of RMB 691.61 million as at 31 December 2025.

Post-transaction, INT Medical will hold a 23.18% stake in Valgen, enhancing its portfolio in structural heart disease treatments and strengthening its competitive position in China’s cardiovascular intervention market.

The acquisition qualifies as a discloseable transaction under Hong Kong Listing Rule 14.07, requiring announcement and reporting but not shareholder approval. INT Medical noted that further share purchases in Valgen could occur, subject to additional regulatory compliance.